322 related articles for article (PubMed ID: 26886317)
1. Physiologically Based Absorption Modeling to Impact Biopharmaceutics and Formulation Strategies in Drug Development-Industry Case Studies.
Kesisoglou F; Chung J; van Asperen J; Heimbach T
J Pharm Sci; 2016 Sep; 105(9):2723-2734. PubMed ID: 26886317
[TBL] [Abstract][Full Text] [Related]
2. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
3. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
O'Dwyer PJ; Box KJ; Dressman J; Griffin BT; Henze LJ; Litou C; Pentafragka C; Statelova M; Vertzoni M; Reppas C
J Pharm Pharmacol; 2021 Mar; 73(4):437-446. PubMed ID: 33793836
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story.
Emami Riedmaier A; Lindley DJ; Hall JA; Castleberry S; Slade RT; Stuart P; Carr RA; Borchardt TB; Bow DAJ; Nijsen M
J Pharm Sci; 2018 Jan; 107(1):495-502. PubMed ID: 28993217
[TBL] [Abstract][Full Text] [Related]
5. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
[TBL] [Abstract][Full Text] [Related]
6. Application of physiologically based absorption and pharmacokinetic modeling in the development process of oral modified release generic products.
Subhani S; Kim C; Muniz P; Rodriguez M; van Os S; Suarez E; Cristofoletti R; Schmidt S; Vozmediano V
Eur J Pharm Biopharm; 2022 Jul; 176():87-94. PubMed ID: 35598768
[TBL] [Abstract][Full Text] [Related]
7. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
[TBL] [Abstract][Full Text] [Related]
8. Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.
Tistaert C; Heimbach T; Xia B; Parrott N; Samant TS; Kesisoglou F
J Pharm Sci; 2019 Jan; 108(1):592-602. PubMed ID: 29906472
[TBL] [Abstract][Full Text] [Related]
9. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.
Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB
Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671
[TBL] [Abstract][Full Text] [Related]
10. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
Eckernäs E; Tannergren C
Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
[TBL] [Abstract][Full Text] [Related]
12. PBPK models for the prediction of in vivo performance of oral dosage forms.
Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
[TBL] [Abstract][Full Text] [Related]
13. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines.
Charalabidis A; Sfouni M; Bergström C; Macheras P
Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154
[TBL] [Abstract][Full Text] [Related]
14. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
Zhang T; Heimbach T; Lin W; Zhang J; He H
J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565
[TBL] [Abstract][Full Text] [Related]
15. Prediction of fasted and fed bioequivalence for immediate release drug products using physiologically based biopharmaceutics modeling (PBBM).
Jereb R; Kristl A; Mitra A
Eur J Pharm Sci; 2020 Dec; 155():105554. PubMed ID: 32946959
[TBL] [Abstract][Full Text] [Related]
16. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
[TBL] [Abstract][Full Text] [Related]
17. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic Modeling of In Vitro Biopharmaceutic Data for a Weak Acid Drug: A Pathway Towards Deriving Fundamental Parameters for Physiologically Based Biopharmaceutic Modeling.
Kowthavarapu VK; Charbe NB; Gupta C; Iakovleva T; Stillhart C; Parrott NJ; Schmidt S; Cristofoletti R
AAPS J; 2024 Apr; 26(3):44. PubMed ID: 38575716
[TBL] [Abstract][Full Text] [Related]
19. Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report.
Mitra A; Suarez-Sharp S; Pepin XJH; Flanagan T; Zhao Y; Kotzagiorgis E; Parrott N; Sharan S; Tistaert C; Heimbach T; Zolnik B; Sjögren E; Wu F; Anand O; Kakar S; Li M; Veerasingham S; Kijima S; Lima Santos GM; Ning B; Raines K; Rullo G; Mandula H; Delvadia P; Dressman J; Dickinson PA; Babiskin A
J Pharm Sci; 2021 Feb; 110(2):594-609. PubMed ID: 33152375
[TBL] [Abstract][Full Text] [Related]
20. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
